These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21103049)

  • 21. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.
    Zhu K; Yan H; Wang R; Zhu H; Meng X; Xu X; Dou X; Chen D
    Med Oncol; 2014 Jul; 31(7):16. PubMed ID: 24861917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
    Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
    Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
    Ma BB; Mo F; Tong JH; Wong A; Wong SC; Ho WM; Wu C; Lam PW; Chan KF; Chan TS; Tsui WM; Tsang AK; Fung MN; Chan AT; To KF
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):160-9. PubMed ID: 25865669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct molecular features of different macroscopic subtypes of colorectal neoplasms.
    Konda K; Konishi K; Yamochi T; Ito YM; Nozawa H; Tojo M; Shinmura K; Kogo M; Katagiri A; Kubota Y; Muramoto T; Yano Y; Kobayashi Y; Kihara T; Tagawa T; Makino R; Takimoto M; Imawari M; Yoshida H
    PLoS One; 2014; 9(8):e103822. PubMed ID: 25093594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
    Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
    Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
    Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
    Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization.
    Sawada T; Yamamoto E; Suzuki H; Nojima M; Maruyama R; Shioi Y; Akasaka R; Kamimae S; Harada T; Ashida M; Kai M; Adachi Y; Yamamoto H; Imai K; Toyota M; Itoh F; Sugai T
    Genes Chromosomes Cancer; 2013 Feb; 52(2):140-9. PubMed ID: 23073979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.